Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus

Science

Volumn 343, Issue 6175, 2014, Pages 1151-1154

  Andrews, Chasity D ^a   Spreen, William R ^b   Mohri, Hiroshi ^a   Moss, Lee ^b   Ford, Susan ^b   Gettie, Agegnehu ^a   Russell Lodrigue, Kasi ^c   Bohm, Rudolf P ^c   Cheng Mayer, Cecilia ^a   Hong, Zhi ^b   Markowitz, Martin ^a   Ho, David D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GSK 744; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG; CABOTEGRAVIR; DELAYED RELEASE FORMULATION; PYRIDONE DERIVATIVE;

CONCENTRATION (COMPOSITION); DRUG; INHIBITOR; PRIMATE; VIRAL DISEASE; VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION PREVENTION; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SINGLE DRUG DOSE; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; DELAYED RELEASE FORMULATION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR GENETICS; PHARMACOKINETICS; RECTUM; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIROLOGY;

ANIMALS; DELAYED-ACTION PREPARATIONS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PYRIDONES; RECTUM; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84896769378     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1248707     Document Type: Article

References (29)

1. UNAIDS, "2013 UNAIDS Report on the Global AIDS Epidemic" (2013); www.unaids.org/en/resources/documents/2013/name,85053,en.asp.
2. Q. Abdool Karim et al., Science 329, 1168-1174 (2010).
3. R. M. Grant et al., N. Engl. J. Med. 363, 2587-2599 (2010).
4. J. M. Baeten et al., N. Engl. J. Med. 367, 399-410 (2012).
5. M. C. Thigpen et al., N. Engl. J. Med. 367, 423-434 (2012).
6. P. L. Anderson et al., Sci. Transl. Med. 4, 151ra125 (2012).
7. L. Van Damme et al., N. Engl. J. Med. 367, 411-422 (2012).
8. J. Marrazzo et al., paper presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3 to 6 March 2013.
9. J. van Lunzen et al., Lancet Infect. Dis. 12, 111-118 (2012).
10. H. J. Stellbrink et al., AIDS 27, 1771-1778 (2013).
11. F. Raffi et al., Lancet 381, 735-743 (2013).
12. F. Raffi et al., Lancet Infect. Dis. 13, 927-935 (2013).
13. S. L. Walmsley et al., N. Engl. J. Med. 369, 1807-1818 (2013).
14. P. Cahn et al., Lancet 382, 700-708 (2013).
15. J. J. Eron et al., J. Infect. Dis. 207, 740-748 (2013).
16. W. R. Spreen, D. A. Margolis, J. C. Pottage Jr., Curr. Opin. HIV AIDS 8, 565-571 (2013).
17. B. A. Johns et al., J. Med. Chem. 56, 5901-5916 (2013).
18. W. Spreen et al., HIV Clin. Trials 14, 192-203 (2013).
19. Y. Lou et al., paper presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 10 to 13 September 2013.
20. W. Spreen et al., paper presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, 30 June to 3 July 2013.
21. W. Spreen et al., paper presented at the 19th International AIDS Conference, Washington, DC, 22 to 27 July 2012.
22. J. Mordenti, J. Pharm. Sci. 75, 1028-1040 (1986).
23. S. M. Moghimi, A. C. Hunter, J. C. Murray, Pharmacol. Rev. 53, 283-318 (2001).
24. S. Subbarao et al., J. Infect. Dis. 194, 904-911 (2006).
25. S. Subbarao et al., J. Med. Primatol. 36, 238-243 (2007).
26. J. G. García-Lerma et al., PLOS Med. 5, e28 (2008).
27. A. J. Hessell et al., Nat. Med. 15, 951-954 (2009).
28. J. G. García-Lerma et al., Sci. Transl. Med. 2, 14ra4 (2010).
29. B. Winner et al., N. Engl. J. Med. 366, 1998-2007 (2012).